Enliven Therapeutics, Inc.
ELVNHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Enliven Therapeutics, Inc. focuses on Biotechnology services and products. Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company carries a $3.80B market cap, placing it firmly in the mid-cap category. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Market Cap
$3.80B
Beta
0.26
P/E (TTM)
—
P/E (Fwd)
-22.88
EPS (TTM)
$-1.72
EPS (Fwd)
$-2.33
ROE
-26.6%
ROA
-18.9%
Cash
$452.4M
Total Debt
$302,000
Free CF
-$46.1M
52W Change
134.8%
Annual Financials
Cash vs Debt
With $452.4M in cash and $302K in debt, ELVN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$46.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Enliven Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ELVN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Enliven Therapeutics, Inc. and its sector.